文献速递乳腺技术与安全US乳腺X线

以色列乳腺影像门诊中COVID-19疫苗接种相关腋窝淋巴结肿大的163例分析

COVID-19 Vaccination Induced Lymphadenopathy in a Specialized Breast Imaging Clinic in Israel: Analysis of 163 cases.
PubMed 文献 · Acad Radiol · 2021-06-10

本研究在以色列乳腺影像门诊中评估接种Pfizer-BioNTech COVID-19疫苗后腋窝淋巴结肿大的发生率和影像特征。结果显示,接种后孤立性腋窝淋巴结肿大病例较前两年增加394%(p=0.00001),第二剂接种后异常淋巴结平均皮质厚度为5±2 mm,长径从15±5 mm增至18±6 mm(p=0.005)。在无症状且以同侧腋窝淋巴结肿大为唯一异常发现的接种女性中,可能无需影像学随访。

要点

  • 接种COVID-19疫苗后腋窝淋巴结肿大发生率显著增加,需在乳腺影像报告中结合接种史考虑。
  • 第二剂接种后淋巴结皮质厚度平均5±2 mm,长径可增至18±6 mm,随访4-5周皮质厚度下降。
  • 仅49%的淋巴结肿大在乳腺X线片上可见,超声是更敏感的检出方法。

关键影像表现/征象

  • 接种后孤立性腋窝淋巴结肿大病例数较前两年增加394%(p=0.00001)。
  • 第二剂接种后异常淋巴结平均皮质厚度为5±2 mm,长径从15±5 mm增至18±6 mm(p=0.005)。
  • 在医务人员亚组中,抗体阳性者淋巴结皮质厚度大于血清学阴性者(p=0.03)。
  • 随访4-5周时淋巴结皮质厚度下降(p=0.007)。
  • 淋巴结肿大在乳腺X线片上仅49%可见。

诊断标准与关键数值

  • 异常淋巴结判定基于皮质厚度和长径测量,第二剂接种后平均皮质厚度5±2 mm,长径15±5 mm至18±6 mm。
  • 抗体阳性与淋巴结皮质厚度较大相关(p=0.03)。

临床应用与阅片要点

  • 询问患者SARS-CoV-2疫苗接种史及接种侧别,以解释同侧腋窝淋巴结肿大。
  • 对于无症状接种女性,若同侧腋窝淋巴结肿大为唯一异常发现,可能无需影像学随访。
  • BRCA携带者接种后淋巴结肿大可同样管理,无需额外干预。

局限性

  • 研究为单中心回顾性设计,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

INTRODUCTION: Following vaccination of Israeli population with Pfizer-BioNTech COVID-19 Vaccine, an unusual increase in axillary-lymphadenopathy was noted. This study assesses the rate and magnitude of this trend from breast-imaging standpoint.

MATERIALS AND METHODS: Participants undergoing breast-imaging, in whom isolated axillary-lymphadenopathy was detected were questioned regarding SARS-CoV-2 vaccine to the ipsilateral arm. Patients' and imaging characteristics were statistically compared. In order to perform a very short-term follow-up, twelve healthy vaccinated medical staff-members, underwent axillary-ultrasound shortly after the second dose, and follow-up.

RESULTS: Axillary-lymphadenopathy attributed to vaccination was found in 163 women undergoing breast-imaging, including BRCA-carriers. During the study, number of detected lymphadenopathies increased by 394% (p = 0.00001) in comparison with previous 2 consecutive years. Mean cortical-thickness of abnormal lymph-nodes after second dose vaccination was 5 ± 2 mm. Longer lymph-node diameter after second vaccination was noted (from 15 ± 5 mm, to 18 ± 6 mm, p = 0.005). In the subgroup of medical staff members, following trends were observed: in patients with positive antibodies, lymph-node cortical-thickness was larger than patients with negative serology (p = 0.03); lymph-node cortical-thickness decreased in 4-5 weeks follow-up (p = 0.007). Lymphadenopathy was evident on mammography in only 49% of cases.

DISCUSSION: Vaccine-associated lymphadenopathy is an important phenomenon with great impact on breast-imaging clinic workload. Results suggest the appearance of cortical thickening shortly after both doses. Positive serology is associated with increased lymph-node cortical-thickness. In asymptomatic vaccinated women with ipsilateral axillary-lymphadenopathy as the only abnormal finding, radiological follow-up is probably not indicated. BRCA-carriers, although at higher risk for breast-cancer, should probably receive the same management as average-risk patients.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Faermann R, Nissan N, Halshtok-Neiman O, et al. COVID-19 Vaccination Induced Lymphadenopathy in a Specialized Breast Imaging Clinic in Israel: Analysis of 163 cases. Acad Radiol. 2021. PMID: 34257025. doi:10.1016/j.acra.2021.06.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。